olivLaw · US equity research
SkinHealth Systems Inc. SKIN
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
SkinHealth Systems (SKIN), known for its flagship Hydrafacial brand, sells skin treatment devices and recurring consumables to providers worldwide. Sales fell in the second quarter of 2026 but adjusted EBITDA came in above guidance, and the company revised its fiscal 2026 outlook to net sales of 280-290 million USD.
At the close of 02 Nov 2026, SkinHealth Systems Inc. (SKIN) stock was 10.38 USD (+4.43% on the day), with market capitalisation 1.4 bn USD, beta -2.27, 52-week range 0.55–12.60 USD. Latest reported quarter (Q2 2026): revenue of 72.1 m USD (−7.8% YoY), net income of -2.7 m USD (−113.5% YoY), diluted EPS -0.02 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 73.3
- overbought (≥ 70)
- Bollinger (20, 2)
- -2.54 – 16.91
- in the upper half of the band · %B 0.66 · band width 270.9%
- SMA 50 / 200
- 3.28 / 1.51
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 2.41 / 2.40
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +1,547.6% | −2.3% | +1,550.0 pp | — |
| 3 months | +1,385.0% | −0.8% | +1,385.8 pp | — |
| 6 months | +1,053.3% | +4.7% | +1,048.6 pp | — |
| Year to date | +646.8% | +10.2% | +636.6 pp | — |
| 1 year | +625.9% | +10.3% | +615.6 pp | −31.4% |
| 3 years | +137.0% | +73.0% | +64.0 pp | −20.8% |
| 5 years | −64.8% | +61.8% | −126.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 78.8 m | 83.5 m | 69.6 m | 78.2 m | 70.7 m | 82.4 m | 64.9 m | 72.1 m |
| Cost of revenue | 38.2 m | 31.1 m | 21.0 m | 29.1 m | 25.0 m | 29.3 m | 20.5 m | 22.8 m |
| Gross profit | 40.6 m | 52.3 m | 48.6 m | 49.1 m | 45.6 m | 53.0 m | 44.4 m | 49.3 m |
| Research & development | 1.1 m | 1.2 m | 998.0 k | 1.3 m | 1.7 m | 1.7 m | 1.1 m | 1.4 m |
| Operating income | -21.5 m | -7.2 m | -12.0 m | -2.7 m | -6.2 m | 162.0 k | -1.8 m | 3.6 m |
| Interest expense | 2.5 m | 2.5 m | 2.5 m | 4.1 m | 6.3 m | 6.4 m | 6.3 m | 6.3 m |
| Pre-tax income | -16.3 m | -11.7 m | -9.2 m | 18.7 m | -10.6 m | -4.8 m | -6.8 m | -1.5 m |
| Income tax | 1.9 m | -1.4 m | 892.0 k | -993.0 k | 386.0 k | 3.3 m | -184.0 k | 1.2 m |
| Net income | -18.3 m | -10.3 m | -10.1 m | 19.7 m | -11.0 m | -8.1 m | -6.6 m | -2.7 m |
| Diluted EPS | -0.15 | -0.07 ≈ | -0.08 | 0.03 | -0.09 | -0.06 ≈ | -0.05 | -0.02 |
| Operating cash flow | 10.3 m ≈ | 16.5 m | 3.0 m | 9.6 m ≈ | 9.6 m ≈ | 15.2 m | -5.6 m | 2.7 m ≈ |
| Capex | 4.0 k ≈ | 74.0 k | 45.0 k | 92.0 k ≈ | 27.0 k ≈ | 139.0 k | 224.0 k | 427.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 166.6 m | 119.1 m | 260.1 m | 365.9 m | 398.0 m | 334.3 m | 300.8 m |
| Revenue YoY | unavailable | −28.5% | +118.4% | +40.7% | +8.8% | −16.0% | −10.0% |
| Net income | -1.6 m | -29.2 m | -378.8 m | 44.2 m | -100.1 m | -29.1 m | -9.5 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | −326.4% | unavailable | unavailable |
| Diluted EPS | -0.05 | -0.85 | -3.71 | -0.23 | -0.76 | -0.36 | -0.16 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -1.0% | -24.5% | -145.6% | 12.1% | -25.2% | -8.7% | -3.2% |
| Free cash flow | -7.0 m | -15.9 m | -39.6 m | -117.4 m | 17.9 m | 15.4 m | 37.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 232.7 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 61.1 m USD
- Total assets
- 499.8 m USD
- Debt / equity
- unavailable
- Current ratio
- 1.66x
- ROE
- -16.9%
- ROA
- -1.6%
- FCF margin
- 12.4%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 119.1 m | 260.1 m | 365.9 m | 398.0 m | 334.3 m | 300.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Cost of revenue | 51.9 m | 81.5 m | 117.1 m | 242.9 m | 152.0 m | 104.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Gross profit | 67.2 m | 178.5 m | 248.8 m | 155.1 m | 182.3 m | 196.4 m | SEC (XBRL)· 12 Mar 2026verified |
| Research & development | 3.4 m | 8.2 m | 8.4 m | 10.1 m | 6.3 m | 5.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Operating income | -17.2 m | -39.9 m | -25.8 m | -130.9 m | -67.8 m | -20.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Interest expense | — | 11.8 m | 13.4 m | 13.6 m | 10.4 m | 19.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Pre-tax income | -38.5 m | -380.6 m | 45.3 m | -101.9 m | -29.6 m | -5.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Income tax | -9.3 m | -1.9 m | 1.1 m | -1.8 m | -452.0 k | 3.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Net income | -29.2 m | -378.8 m | 44.2 m | -100.1 m | -29.1 m | -9.5 m | SEC (XBRL)· 12 Mar 2026verified |
| Diluted EPS | -0.85 | -3.71 | -0.23 | -0.76 | -0.36 | -0.16 | SEC (XBRL)· 12 Mar 2026verified |
| Weighted average diluted shares | 34.3 m | 102.1 m | 148.5 m | 131.7 m | 142.5 m | 135.8 m | SEC (XBRL)· 12 Mar 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 9.5 m | 901.9 m | 568.2 m | 523.0 m | 370.1 m | 232.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Receivables | 18.6 m | 46.8 m | 76.5 m | 54.7 m | 27.6 m | 21.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Inventories | 23.2 m | 35.3 m | 109.7 m | 91.3 m | 69.1 m | 48.0 m | SEC (XBRL)· 12 Mar 2026verified |
| Current assets | 59.1 m | 1.0 bn | 783.3 m | 698.3 m | 477.1 m | 309.5 m | SEC (XBRL)· 12 Mar 2026verified |
| Property, plant & equipment, net | 9.2 m | — | — | — | — | — | SEC (XBRL)· 13 Aug 2021verified |
| Goodwill | 98.5 m | 123.7 m | 124.6 m | 125.8 m | 123.5 m | 126.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Intangibles (excl. goodwill) | 50.9 m | 56.0 m | 46.4 m | 62.1 m | 47.5 m | 35.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Total assets | 222.8 m | 1.2 bn | 1.0 bn | 929.1 m | 685.7 m | 499.8 m | SEC (XBRL)· 12 Mar 2026verified |
| Accounts payable | 18.5 m | 29.0 m | 28.5 m | 44.8 m | 21.9 m | 15.6 m | SEC (XBRL)· 12 Mar 2026verified |
| Long-term debt | — | — | — | — | 552.2 m | — | SEC (XBRL)· 07 Aug 2025verified |
| Current liabilities | 30.9 m | 76.4 m | 71.7 m | 115.0 m | 68.2 m | 186.3 m | SEC (XBRL)· 12 Mar 2026verified |
| Total liabilities | 252.8 m | 916.5 m | 836.0 m | 869.7 m | 633.9 m | 438.7 m | SEC (XBRL)· 12 Mar 2026verified |
| Equity | -30.6 m † | 298.0 m † | 167.1 m † | 59.4 m † | 51.8 m † | 61.1 m † | SEC (XBRL)· 12 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -12.4 m | -28.4 m | -106.6 m | 21.8 m | 16.1 m | 37.5 m | SEC (XBRL)· 12 Mar 2026verified |
| Capex | 3.5 m | 11.2 m | 10.8 m | 3.8 m | 756.0 k | 303.0 k | SEC (XBRL)· 12 Mar 2026verified |
| Free cash flow | -15.9 m ≈ | -39.6 m ≈ | -117.4 m ≈ | 17.9 m ≈ | 15.4 m ≈ | 37.2 m ≈ | SEC (XBRL)· 12 Mar 2026derived |
| Investing cash flow | -3.8 m | -37.7 m | -18.9 m | -31.5 m | -6.8 m | -5.2 m | SEC (XBRL)· 12 Mar 2026verified |
| Financing cash flow | 18.3 m | 959.0 m | -205.2 m | -37.4 m | -158.3 m | -174.9 m | SEC (XBRL)· 12 Mar 2026verified |
| Share repurchases | 154.0 k | 0 | 160.0 m | 30.2 m | 0 | 0 | SEC (XBRL)· 12 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 39.6% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
02 Nov 2026Source: olivLaw, closing series
Market cap: 1.4 bn USD
Key indicators
Coverage and freshness
Score by group
40% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 39.6% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -9.8% | 43 (vs peers) | 16% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -6.3% | 0 (on a fixed band) | 21% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -0.2x | 0 (on a fixed band) | 16% |
| Current ratio · Balance sheet | 1.8x | 80 (on a fixed band) | 11% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 1.6% | 20 (on a fixed band) | 21% |
| Shareholder yield (distributions) · Returns | 0.0% | 0 (on a fixed band) | 16% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet32/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial43/100 · 1/3 factors with a value
- Returns· partial0/100 · 1/2 factors with a value
- Valuation· partial20/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
SkinHealth Systems Inc. (SKIN). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 300.8 m USD in 2025; YoY growth -10.0%; net margin -9.8%; ROE -43.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 39.6% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 1.8x
What contradicts it
- Revenue CAGR 3Y: -6.3%
- Interest coverage: -0.2x
- FCF yield: 1.6%
- Shareholder yield (distributions): 0.0%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 116.8 bn | 32.7 | 16.0% | 13.8% | +11.2% | −17% / +4% |
| MMM3m Company | 92.2 bn | 26.6 | 80.8% | 14.0% | +1.5% | +4% / +115% |
| BSXBoston Scientific Corporation | 64.2 bn | 18.8 | 14.3% | 16.6% | +19.9% | −56% / −21% |
| BDXBecton, Dickinson And Company | 54.1 bn | 60.0 | 3.8% | 4.0% | +8.2% | +30% / +7% |
| RMDResMed Inc. | 32.8 bn | 21.2 | 26.4% | 27.8% | +9.9% | −9% / +48% |
| DXCMDexcom, Inc. | 31.6 bn | 33.4 | 37.7% | 19.4% | +15.6% | +34% / −27% |
| WSTWest Pharmaceutical Services, Inc. | 28.4 bn | 45.8 | 21.2% | 18.8% | +6.3% | +47% / +16% |
| GKOSGLAUKOS Corp | 14.1 bn | — | -22.8% | -24.6% | +32.3% | +124% / +273% |
| BAXBaxter International Inc. | 12.5 bn | — | -10.5% | -6.2% | +5.7% | +29% / −33% |
| HAEHaemonetics Corporation | 5.5 bn | 58.7 | 11.2% | 7.1% | −2.0% | +48% / +49% |
| MMSIMerit Medical Systems Inc | 5.1 bn | 31.7 | 9.8% | 9.9% | +11.8% | −3% / +18% |
| HTFLHeartflow, Inc. | 4.7 bn | — | — | -55.8% | +39.9% | +69% / unavailable |
| UFPTUFP Technologies, Inc. | 2.2 bn | 30.6 | 17.1% | 11.4% | +19.5% | +25% / +71% |
| INSPInspire Medical Systems, Inc. | 1.9 bn | 19.6 | 13.5% | 11.4% | +13.6% | −46% / −54% |
| SKINSkinHealth Systems Inc. | 1.4 bn | — | -43.9% | -9.8% | −10.0% | +626% / +137% |
| IARTIntegra Lifesciences Holdings Corp | 1.1 bn | 81.1 | 1.2% | 0.8% | +1.5% | +4% / −65% |
| BBNXBeta Bionics, Inc. | 864.4 m | — | -23.9% | -65.3% | +53.9% | −49% / unavailable |
| TCMDTactile Systems Technology, Inc. | 512.3 m | 22.3 | 11.0% | 6.7% | +12.5% | −11% / +72% |
| MDXGMimedx Group, Inc. | 478.6 m | — | -8.5% | -6.3% | +20.0% | −52% / −58% |
| SSIISs Innovations International, Inc. | 462.9 m | — | -26.1% | -23.7% | +105.7% | −66% / unavailable |
| OFIXOrthofix Medical Inc. | 356.4 m | — | -13.9% | -7.4% | +2.9% | −46% / −21% |
| CTSOCytosorbents Corporation | 258.9 m | — | -336.2% | -48.9% | +4.1% | −75% / −83% |
| PROFProfound Medical Corp. | 245.9 m | — | -73.5% | -171.6% | +50.7% | +2% / −38% |
| UTMDUtah Medical Products, Inc. | 224.6 m | 21.5 | 8.8% | 29.0% | −5.8% | +25% / −16% |
| KRMDKoru Medical Systems, Inc. | 140.8 m | — | -10.5% | -4.0% | +22.2% | −48% / +35% |
1- and 3-year price returns: for SKIN from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
SkinHealth Systems (SKIN), known for its flagship Hydrafacial brand, sells skin treatment devices and recurring consumables to providers worldwide. Sales fell in the second quarter of 2026 but adjusted EBITDA came in above guidance, and the company revised its fiscal 2026 outlook to net sales of 280-290 million USD 123.
SWOT
Strengths
- The Hydrafacial brand is globally recognised and backed by a large worldwide installed base, which supports a steady flow of consumables 1.
- The recurring consumables model reduces dependence on equipment sales, which are cyclical 1.
- Gross margin improved in 2026 and adjusted EBITDA exceeded the guidance range, showing cost discipline 3.
Weaknesses
- Sales of new systems fell significantly, and total revenue contracted in 2025 and the first half of 2026 13.
- The company reported net losses in 2025 and 2026, and net results depend on interest costs and non-recurring items 13.
- A history of performance problems in earlier generations of the Syndeo system affected reputation and generated remediation costs 1.
Opportunities
- If utilisation of the installed base rises, consumables revenue could return to growth 1.
- Expanding the portfolio with SkinStylus and complementary technologies could open new revenue streams for providers 1.
- Partnership distribution and technology partnerships could lower costs and speed entry into new markets 12.
Risks
- Decline in system saleshigh
If providers keep deferring equipment purchases, device revenue could remain below last year's level and weigh on total results 13.
- Net losses and debt costshigh
The company has reported net losses and carries high interest costs on its notes, which could limit financial flexibility if results do not improve 13.
- Product quality issuesmedium
Technical defects in earlier generations of the Syndeo system led to high return rates, and any new issue could damage the brand 1.
- Counterfeiting and diversionmedium
Counterfeit or diverted products could compromise user safety and the brand's image 1.
- Supply chain exposuremedium
Single sources for certain components and reliance on contract manufacturers could delay production if war, disasters or epidemics occur 1.
Investment thesis
What would need to be true (bull case)
- Adjusted EBITDA rose in the second quarter and exceeded guidance, and gross margin improved, which could show an ability to protect profitability even with weaker sales 3.
- The active install base grew year on year, and recurring consumables could become a steadier support if utilisation improves 13.
- If the partner-led distribution strategy lowers operating costs without losing clients, the company could have a more efficient structure over the longer term 2.
What would break the thesis
- Sales declined in 2025 and in the second quarter of 2026, and the revised fiscal 2026 outlook reflects continued pressure on sales 3.
- The company continues to report net losses and carries high interest costs, which could limit investment capacity if demand does not recover 13.
- If providers and consumers cut spending on aesthetic treatments because of economic conditions, consumables revenue could also decline 12.
What to watch
- Results of new system sales and the number of systems placedQ3 2026
- Delivery against the revised guidance for net sales and adjusted EBITDAQ3 2026
- Trends in the active install base and consumables utilisationnext 10-K
- Effects of the shift to distributors in Australia and New Zealand on revenue and costs2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The company describes itself as a global medical aesthetics company whose core product is the Hydrafacial system, a patented hydradermabrasion treatment, supplemented by SkinStylus for microneedling and nano-channeling and HydraScalp powered by Keravive for the scalp 1. Its economic model is razor/razor blade: Delivery Systems are sold as capital equipment, while consumables (single-use tips, solutions, serums) generate recurring revenue as the installed base grows 1. Delivery Systems are manufactured in Long Beach, California, while many other components are made by external suppliers in North America, Europe and Asia 1.
According to the annual report, consumables revenue grew in 2025 on system placements and price increases, while Delivery System sales declined sharply 1. The company moved China sales to a distributor in 2025 and did the same for Australia and New Zealand in June 2026 12. These changes are presented as part of a strategy to align the distribution model with in-market partner capabilities 2.
The stated strategy has three pillars: disciplined selling with a value-based approach, marketing focused on consumer demand, and innovation centred on clinically supported technologies, including a next generation of Hydrafacial systems intended to drive upgrades across the installed base 1.
Market context
The active install base, estimated at 36516 systems at June 30 2026, rose from 35193 a year earlier, indicating that utilisation of the existing base remains the main source of recurring revenue 3. If utilisation of the installed base improves, consumables revenue could support total sales even while system sales remain weak 1.
Trends
- Pressure on equipment spendingheadwind
Providers are deferring purchases of new systems amid tighter economic and credit conditions, which reduced device sales in 2025 and the first half of 2026 12.
- Demand for non-invasive treatmentstailwind
Consumers prioritise skin health and non-invasive treatments, and practices are favouring technologies that attract clients and support combined protocols 1.
- Tariffs and trade restrictionsheadwind
Tariffs and trade restrictions could raise material costs and prices, and the company acknowledges that price adjustments may reduce demand 12.
- Shift to partner-led distributionmixed
Moving sales to distributors in China and in Australia and New Zealand may reduce direct revenue, but the company states the change could be accretive to long-term profitability 2.
Competitive position
The industry is highly competitive, with large multinational consumer products companies owning many beauty brands, standalone skincare brands and newer companies backed by influencers 1. Larger competitors generally have greater financial and marketing resources than the company and may respond better to price cuts and market changes 1.
The company differentiates itself through the Hydrafacial brand, its global installed base and proprietary consumables supported by clinical data, but competition in microneedling and nano-channeling, where SkinStylus participates, is growing 1.
- Multinational consumer products groups with beauty lines
The source refers to several large international groups with many beauty brands and greater marketing and financial resources than the company 1.
- Independent skincare brands and influencer-backed companies
These have emerged in recent years with large followings and can quickly shift consumer preferences 1.
- Microneedling and nano-channeling technology makers
These compete in the category where SkinStylus aims to grow, which the source describes as expanding 1.
- Local distributors in markets where the company moved to indirect sales
The company transferred sales to partners in China and in Australia and New Zealand, so these partners now compete for provider attention 12.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report14 Oct 2026Item 3.03 · Amendments to articles or bylaws · Regulation FD disclosure · Financial statements and exhibits
- Current report06 Oct 2026Termination of a material agreement · Regulation FD disclosure
- Current report28 Sept 2026Shareholder vote
- Current report10 Sept 2026Departure or appointment of officers
- Current report14 Aug 2026Departure or appointment of officers
- Proxy statement12 Aug 2026
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report22 Jun 2026Other events
- Current report16 Jun 2026Shareholder vote
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / SkinHealth Systems Inc. · 12 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / SkinHealth Systems Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / SkinHealth Systems Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.